Skip to main content
SpringerLink
Log in

Safe Opioid Prescribing and Controlled Substance Policies

  • Chapter
  • First Online:
Leading an Academic Medical Practice

  • 550 Accesses

Abstract

Chronic opioid therapy is frequently utilized when patients suffer from persistently severe and disabling pain, but it is often associated with a myriad of prescribing challenges and clinical risks. This chapter explores the potential risks and benefits of chronic opioid use and how to anticipate, prevent, and mitigate these risks in a busy academic outpatient clinic.

Author’s Note: Although we focus on opioid prescribing throughout this chapter, many of the identified practice management principles also apply to other controlled substances (such as benzodiazepines, other sedatives, and stimulants).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Institute of Medicine (U.S.). Committee on Advancing Pain Research Care and Education. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, D.C.: National Academies Press; 2011. http://www.nap.edu/openbook.php?record_id=13172

    Google Scholar 

  2. Roehr B. US needs new strategy to help 116 million patients in chronic pain. BMJ. 2011;343:d4206.

    Article  PubMed  Google Scholar 

  3. Breuer B, Pappagallo M, Tai JY, Portenoy RK. U.S. board-certified pain physician practices: uniformity and census data of their locations. J Pain. 2007;8(3):244–50.

    Article  PubMed  Google Scholar 

  4. Chou R, Turner JA, Devine EB, Hansen RN, Sullivan SD, Blazina I, et al. The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop. Ann Intern Med. 2015;162(4):276–86.

    Article  PubMed  Google Scholar 

  5. Committee on Advancing Pain Research Care, Institute of Medicine. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington, DC: National Academies Press; 2011. Report No.: 030921484X.

    Google Scholar 

  6. Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009;10(2):113–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Painter JT, Crofford LJ. Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol. 2013;19(2):72–7.

    Article  PubMed  Google Scholar 

  8. Qaseem A, Wilt TJ, McLean RM, Forciea MA. Clinical Guidelines Committee of the American College of P. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166(7):514–30.

    Article  PubMed  Google Scholar 

  9. Tobin DG, Andrews R, Becker WC. Prescribing opioids in primary care: safely starting, monitoring, and stopping. Cleve Clin J Med. 2016;83(3):207–15.

    Article  PubMed  Google Scholar 

  10. The Opioid Epidemic: By the Numbers: Department of Health and Human Services; 2016 [updated June, 2016]. https://www.hhs.gov/sites/default/files/Factsheet-opioids-061516.pdf

  11. Bronstein K, Passik S, Munitz L, Leider H. Can clinicians accurately predict which patients are misusing their medications? Austin; 2011. American Pain Society 30th Annual Scientific Meeting; 18–21 May 2011.

    Google Scholar 

  12. Webster LR. Opioid-induced constipation. Pain Med. 2015;16(Suppl 1):S16–21.

    Article  PubMed  Google Scholar 

  13. Brennan MJ. The effect of opioid therapy on endocrine function. Am J Med. 2013;126(3 Suppl 1):S12–8.

    Article  CAS  PubMed  Google Scholar 

  14. Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14(2):145–61.

    PubMed  Google Scholar 

  15. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict. 2010;19(1):4–16.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Paulozzi L, Dellinger A, Degutis L. Lessons from the past. Injury Prev. 2012;18(1):70.

    Article  Google Scholar 

  17. Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64(50-51):1378–82.

    Article  PubMed  Google Scholar 

  18. Bohnert AS, Valenstein M, Bair MJ, Ganoczy D, McCarthy JF, Ilgen MA, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA. 2011;305(13):1315–21.

    Article  CAS  PubMed  Google Scholar 

  19. U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning 2016 [updated 31 Aug 2016]. https://www.fda.gov/Drugs/DrugSafety/ucm518473.htm

  20. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016;315(15):1624–45.

    Article  CAS  PubMed  Google Scholar 

  21. American Psychiatric Association. DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington, D.C.: American Psychiatric Association; 2013. xliv, 947p.

    Google Scholar 

  22. Vowles KE, McEntee ML, Julnes PS, Frohe T, Ney JP, van der Goes DN. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain. 2015;156(4):569–76.

    Article  PubMed  Google Scholar 

  23. Longo LP, Parran T, Johnson B, Kinsey W. Addiction: part II. Identification and management of the drug-seeking patient. Am Fam Physician. 2000;61(8):2401–8.

    CAS  PubMed  Google Scholar 

  24. Eichorn D, Lesenskyj A, Maxwell C, Moore S, Cruciani R. (195) The feasibility and value of using the SOAPP(R)-R to predict substance abuse in an outpatient pain clinic. J Pain. 2016;17(4S):S24.

    Article  Google Scholar 

  25. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–42.

    Article  PubMed  Google Scholar 

  26. Nicolaidis C. Police officer, deal-maker, or health care provider? Moving to a patient-centered framework for chronic opioid management. Pain Med. 2011;12(6):890–7.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009;24(6):733–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Penko J, Mattson J, Miaskowski C, Kushel M. Do patients know they are on pain medication agreements? Results from a sample of high-risk patients on chronic opioid therapy. Pain Med. 2012;13(9):1174–80.

    Article  PubMed  PubMed Central  Google Scholar 

  29. McGee S, Silverman RD. Treatment agreements, informed consent, and the role of state medical boards in opioid prescribing. Pain Med. 2015;16(1):25–9.

    Article  PubMed  Google Scholar 

  30. Tobin DG, Keough Forte K, Johnson McGee S. Breaking the pain contract: a better controlled-substance agreement for patients on chronic opioid therapy. Cleve Clin J Med. 2016;83(11):827–35.

    Article  PubMed  Google Scholar 

  31. Starrels JL, Becker WC, Alford DP, Kapoor A, Williams AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712–20.

    Article  PubMed  Google Scholar 

  32. King S. How useful are patient opioid agreements and urine drug testing? | Psychiatric Times 2011. http://www.psychiatrictimes.com/how-useful-are-patient-opioid-agreements-and-urine-drug-testing

  33. Cotugna N, Vickery CE, Carpenter-Haefele KM. Evaluation of literacy level of patient education pages in health-related journals. J Community Health. 2005;30(3):213–9.

    Article  PubMed  Google Scholar 

  34. U.S. Department of Justice, Office of Diversion Control, Title 21 Code of Federal Regulations - PART 1300 - DEFINITIONS 2015. http://www.deadiversion.usdoj.gov/21cfr/cfr/1300/1300_01.htm

  35. United States. Congress. Senate. Committee on Health Education Labor and Pensions. Prescription drug abuse and diversion: the role of prescription drug monitoring programs: hearing before the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Eighth Congress, second session, on examining drug abuse prevention issues, focusing on the role of prescription drug monitoring programs, and federal privacy standards for PMPS, September 23, 2004. Washington: U.S. G.P.O.: For sale by the Supt. of Docs., U.S. G.P.O.; 2005. iii, 57p.

    Google Scholar 

  36. Centers for Medicare and Medicaid Services. Tamper resistant prescriptions 2013 [updated April 9, 2013]. http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/FraudAbuseforProfs/TRP.html

  37. Nelson LS, Perrone J. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA. 2012;308(5):457–8.

    Article  CAS  PubMed  Google Scholar 

  38. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep. 2016;65(1):1–49.

    Article  PubMed  Google Scholar 

  39. CEDIA Opiate Assay: Thermo Scientific; 2015. http://www.thermoscientific.com/content/dam/tfs/SDG/CDD/CDD%20Documents/Package%20Inserts/Diagnostic%20Testing%20Reagents/Drug%20of%20Abuse%20Testing%20(DAT)%20Calibrators%20Controls%20and%20Reagents/Drug%20of%20Abuse%20Reagents/10006508-3-Opiate-Assay-EN.pdf

  40. Dasgupta A. Urinary adulterants and drugs-of-abuse testing. MLO Med Lab Obs. 2003;35(2):26–8, 30–1.

    PubMed  Google Scholar 

  41. Cone EJ, Bigelow GE, Herrmann ES, Mitchell JM, LoDico C, Flegel R, et al. Non-smoker exposure to secondhand cannabis smoke. I. Urine screening and confirmation results. J Anal Toxicol. 2015;39(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  42. Röhrich J, Schimmel I, Zörntlein S, Becker J, Drobnik S, Kaufmann T, et al. Concentrations of delta9-tetrahydrocannabinol and 11-nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to Cannabis smoke in a coffee shop. J Anal Toxicol. 2010;34(4):196–203.

    Article  PubMed  Google Scholar 

  43. Niedbala RS, Kardos KW, Fritch DF, Kunsman KP, Blum KA, Newland GA, et al. Passive cannabis smoke exposure and oral fluid testing. II. Two studies of extreme cannabis smoke exposure in a motor vehicle. J Anal Toxicol. 2005;29(7):607–15.

    Article  CAS  PubMed  Google Scholar 

  44. Tobin DG. A rational approach to opioid use disorder in primary care. Cleve Clin J Med. 2017;84(5):385–7.

    Article  PubMed  Google Scholar 

  45. Martin BC, Fan MY, Edlund MJ, Devries A, Braden JB, Sullivan MD. Long-term chronic opioid therapy discontinuation rates from the TROUP study. J Gen Intern Med. 2011;26(12):1450–7.

    Article  PubMed  PubMed Central  Google Scholar 

  46. National Guideline Clearinghouse. Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy. Rockville: Agency for Healthcare Research and Quality (AHRQ); 2010. http://www.guideline.gov/content.aspx?id=23792

  47. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services. Partners in integrity: what is the prescriber’s role in preventing the diversion of prescription drugs 2014. http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Provider-Education-Toolkits/Downloads/prescriber-role-drugdiversion.pdf

  48. U.S. Food and Drug Administration. Disposal of unused medicines: what you should know 2017 [updated April 21, 2017]. https://www.fda.gov/drugs/resourcesforyou/consumers/buyingusingmedicinesafely/ensuringsafeuseofmedicine/safedisposalofmedicines/ucm186187.htm

Download references

Author information

Authors and Affiliations

  1. Yale-New Haven Hospital, Yale University School of Medicine, New Haven, CT, USA

    Daniel G. Tobin M.D., F.A.C.P.

  2. Barnes Jewish Hospital, Washington University School of Medicine, St. Louis, MO, USA

    Ernie-Paul Barrette M.D., F.A.C.P.

Authors
  1. Daniel G. Tobin M.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ernie-Paul Barrette M.D., F.A.C.P.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel G. Tobin M.D., F.A.C.P. .

Editor information

Editors and Affiliations

  1. Baylor College of Medicine, Houston, Texas, USA

    Lee Bach Lu

  2. Washington University School of Medicine, St. Louis, Missouri, USA

    Ernie-Paul Barrette

  3. Boston University School of Medicine, Boston, Massachusetts, USA

    Craig Noronha

  4. University of Vermont, Robert Larner M.D. College of Medicine, Burlington, Vermont, USA

    Halle G. Sobel

  5. Yale University School of Medicine, New Haven, Connecticut, USA

    Daniel G. Tobin

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Tobin, D.G., Barrette, EP. (2018). Safe Opioid Prescribing and Controlled Substance Policies. In: Lu, L., Barrette, EP., Noronha, C., Sobel, H., Tobin, D. (eds) Leading an Academic Medical Practice. Springer, Cham. https://doi.org/10.1007/978-3-319-68267-9_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-68267-9_14

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-68266-2

  • Online ISBN: 978-3-319-68267-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation